Beskrivning:

A Phase III Trial of ZD4054 (Zibotentan) (Endothelin A Antagonist) in Non-metastatic Hormone Resistant Prostate Cancer (ENTHUSE M0) see http://clinicaltrials.gov/ct2/show/study/NCT00626548

Länk:
http://clinicaltrials.gov/ct2/show/study/NCT00626548
Nyckelord:
  1. 2011-11-22 2011-11-22 -
  2. 2011-11-22 2011-11-22 -
  3. 2014-03-27 2014-03-27 - Martin Dugas
  4. 2014-04-13 2014-04-13 - Julian Varghese
  5. 2021-09-17 2021-09-17 -
Uppladdad den:

17 september 2021

DOI:
För en begäran logga in.
Licens :
Creative Commons BY 4.0
Modellkommentarer :

Här kan du kommentera modellen. Med hjälp av pratbubblor i Item-grupperna och Item kan du lägga in specifika kommentarer.

Itemgroup-kommentar för :

Item-kommentar för :

Du måste vara inloggad för att kunna ladda ner formulär. Var vänlig logga in eller registrera dig utan kostnad.

Eligibility DRKS00003883 NCT00626548 Prostate Cancer

Eligibility NCT00626548

  1. StudyEvent: Eligibility
    1. Eligibility NCT00626548
Inclusion criteria
18 Years and older
Male
Confirmed diagnosis of prostate cancer (adenocarcinoma of the prostate) that has NOT spread to the other parts of the body (metastases). Patients with lymph node involvement may be eligible if specified criteria is met.
Increasing Prostate Specific Antigen (PSA), collected within one year of enrollment
Currently receiving treatment with surgical or medical castration
Exclusion criteria
Currently using opiate based pain killers for cancer related pain
Previous treatment with chemotherapy (paclitaxel, docetaxel, and mitoxantrone). Prior targeted cancer therapies are permitted if received during a previous clinical trial
Suffering from heart failure or had a myocardial infarction within last 6 months
A history of epilepsy or seizures

Similar models

Använd detta formulär för feedback, frågor och förslag på förbättringar.

Fält markerade med * är obligatoriska.

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial